{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-023342","form_type":"8-K/A","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2022-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.973415+00:00","generated_at":"2026-06-23T23:01:36.745065+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"confidence":"high","headline":"GT Biopharma amends 8-K to correct vote tabulation on authorized shares reduction","bullets":["Proposal 4 to reduce authorized shares from 750M to 250M passed with 19,568,632 For, 215,253 Against, 141,506 Abstain.","Original filing incorrectly classified Proposal 4 as non-routine; it was routine, allowing broker discretionary votes.","Company plans special stockholder meeting to ratify inclusion of discretionary broker votes in Proposal 4 tabulation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-023342","json":"https://secwatch.observer/filing/0001493152-22-023342.json","markdown":"https://secwatch.observer/filing/0001493152-22-023342.md","text":"https://secwatch.observer/filing/0001493152-22-023342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315222023342/0001493152-22-023342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315222023342/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:01:36.745065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}